CERA

Science and Research

LUCERNE: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

This 112-week study aims to evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab, compared with aflibercept (Eylea), in patients with choroidal neovascularization secondary to age-related macular degeneration.

Overview

This 112-week study aims to evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab, compared with aflibercept (Eylea), in patients with choroidal neovascularization secondary to age-related macular degeneration.

  • Principal Investigator
Dr Sukhpal Sandhu

Learn more

View this study at ClinicalTrials.gov

This international database listing provides more detailed information about this study.